Biontech Announces Closure of Multiple Facilities in Germany
Daily Monitor
May 5, 2026
Biontech Announces Closure of Multiple Facilities in Germany
Biontech plans to close sites in Idar-Oberstein, Marburg, Singapore, and Tübingen, potentially resulting in the loss of up to 1,860 jobs.
The company aims to save approximately €500 million by 2029, reallocating funds towards cancer drug research. Following a significant financial loss last year, Biontech anticipates reduced revenues from COVID-19 vaccine sales in both European and U.S. markets. The firm is preparing to develop a variant-adapted COVID-19 vaccine for the 2026/27 season. Co-founders Ugur Sahin and Özlem Türeci are set to leave the company to establish a new venture focused on research.
For journalistic integrity, this report was summarized from: deutschlandfunk.de